2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Li Zhang, MD, discusses sacituzumab tirumotecan in patients with previously treated, advanced EGFR-mutated non–small cell lung cancer.
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
“The ORR in the sacituzumab tirumotecan group was significantly higher compared with docetaxel at 45.1% vs 15.6%, [respectively].”
Li Zhang, MD, deputy director of the Lung Cancer Research Center and professor in the Medical Oncology Department at Sun Yat-sen University Cancer Center, discussed efficacy data from the phase 2 OptiTROP-Lung03 trial (NCT05631262) of sacituzumab tirumotecan in patients with previously treated, advanced EGFR-mutated non–small cell lung cancer (NSCLC).
OptiTROP-Lung03 enrolled patients with nonsquamous NSCLC with an ECOG performance status of 0 or 1 who experienced disease progression following prior combination or sequential treatment with EGFR TKIs and platinum-based chemotherapy. Eligible patients were randomly assigned 2:1 to receive 5 mg/kg of intravenous (IV) sacituzumab tirumotecan every 2 weeks or IV docetaxel at a dose of 75 mg/m2 every 3 weeks. The primary end point was overall response rate (ORR) per blinded independent review committee (BIRC); secondary end points included progression-free survival (PFS) and overall survival (OS).
During the 2025 ASCO Annual Meeting, Zhang presented data from OptiTROP-Lung03 that demonstrated that patients who received sacituzumab tirumotecan (n = 91) achieved a confirmed ORR by BIRC of 45.1% (95% CI, 34.6%-55.8%) vs 15.6% (95% CI, 6.5%-29.5%) in the docetaxel arm (n = 45). These values represented a difference in ORR of 28.9% (95% CI, 14.5%-43.2%; 1-sided P = .0004), which was a significant improvement in favor of the investigational arm, Zhang noted. The median PFS by BIRC was 6.9 months (95% CI, 5.4-8.2) in the sacituzumab tirumotecan arm compared with 2.8 months (95% CI, 1.6-4.1) in the docetaxel arm (n = 46), representing an HR of 0.30 (95% CI, 0.20-0.46; P < .0001), which was highly significant, he added.
At a median follow-up of 12.2 months, the median OS adjusted for crossover was not reached (95% CI, not estimable [NE]-NE) in the investigational arm compared with 9.3 months (95% CI, 7.3-NE) in the control arm. The 12-month OS rates were 72.8% and 43.2%, respectively. The HR for OS was 0.36 (95% CI, 0.20-0.66) in favor of the sacituzumab tirumotecan arm, which was highly significant, Zhang concluded.
Related Content: